International Conference on Advanced Technologies and Treatments for Diabetes

Hybrid closed-loop insulin delivery systems are more cost-effective for treating type 1 diabetes than immune therapies unless the effects of immune therapies are persistent over a lifetime after one course, according to a speaker.

Pregnant women with type 1 diabetes achieved a higher time in range and had fewer complications with use of a hybrid closed-loop insulin delivery system compared with continuous glucose monitoring alone, according to a speaker.

A once-weekly basal insulin conferred similar changes in HbA1c and time in range as once-daily insulin glargine among adults with type 1 and type 2 diabetes in three phase 2 trials, according to a speaker.

Bariatric surgery will continue to be a therapeutic option for obesity and early diabetes in the future and may be used in combination with newer medications, according to a speaker.

Providers should use both HbA1c values and continuous glucose monitoring data to manage diabetes and prevent complications, though HbA1c should remain the standard for diagnosing diabetes, according to two speakers.

Using a pod-based automated insulin delivery system can provide glycemic benefits for people with type 2 diabetes, according to a speaker at the International Conference on Advanced Technologies & Treatments for Diabetes.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.